Journal of Stem Cell Research & Therapy

Relationship between cytochrome P450 polymorphisms and prescribed medication in elderly haemodialysis patients

6^th International Conference and Exhibition on Cell and Gene Therapy

March 27-28, 2017 Madrid, Spain

Krystina Parker

Akershus University Hospital, Norway
University of Oslo, Norway

Scientific Tracks Abstracts: J Stem Cell Res Ther

Abstract:

Background: Elderly patients on haemodialysis treatment have polypharmacy. The drug response can be influenced by age, smoking, as well as through the genetic variations in the cytochrome P450 (CYP) enzymes system. More than 80% of all prescribed drugs are metabolized by CYP enzymes. Aims of this study were to describe the prevalence of polymorphism in 3 CYP isoenzymes and the relationship between CYP polymorphism and prescribed drugs. Methods: 51 elderly haemodialysis patients aged â?¥65 years were included. CYP-genotyping was carried out in whole blood by a realtime PCR method for detecting common variant alleles in CYP2C9, CYP2C19 and CYP2D6. The allele frequencies were calculated using the Hardy-Weinberg equation. Results: The overall prevalence of CYP polymorphisms (heterozygous and homozygous) was 77%. The prevalence of heterozygous carriers of variant alleles coding for defective CYP2D6, CYP2C9 and CYP2C19 was 64%, 22% and 55%, respectively. The prevalence of homozygous carriers was 6% for each of the CYP2D6, CYP2C9 and CYP2C19 enzymes. The prevalence of CYP2D6*6, CYP2D6*9 and CYP2D6*41 variant alleles did not differ from that in a European Caucasian reference population (p=0.31). 23 patients (45%) had at least one CYP mutation and used drugs that are metabolized by CYP isoenzymes. Metoprolol and proton-pump inhibitors were the most commonly used drugs that could be affected by a heterozygous or homozygous mutation. Conclusions: Polymorphisms of CYP2C9, CYP2C19 and CYP2D6 are common in elderly haemodialysis patients. Many of these patients have a phenotype with altered CYP enzyme activity and could benefit from close drug monitoring.

Biography :

Krystina Parker is a Specialist in Internal Medicine with ten years of experience. In the last five years, she has been a Consultant in the Nephrology department of Akershus University Hospital. She is currently working on her PhD at the University of Oslo which includes teaching medical students at various stages of their study. She is a Co-author in various projects including “Increased levels of inflammatory mediators and proinflammatory monocytes in patients with type I diabetes mellitus and nephrology” and “Glucarpidase (Carboxypeptidase G2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy”.

Email: krystina.parker@medisin.uio.no